135036-22-5

Upstream product

• 4554-16-9 2,3-dibromopropionitrile 
• 58077-34-2 N¹-benzyl-N²-phenylethane-1,2-diamine 

Downstream Products

• 135036-24-7 4-[(Methylsulfonyl)amino]-N-[[1-phenyl-4-(phenylmethyl)piperazin-2-yl]methyl] benzamide 
• 135036-09-8 4-[(methylsulfonyl)amino]-N-[(1-phenylpiperazin-2-yl)methyl]benzamide 
• 135036-23-6 1-phenyl-4-(phenylmethyl)-2-piperazinemethanamine 

Relevant academic research and scientific papers

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These componds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Alpha 1a adrenergic receptor antagonist

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Synthesis, cardiac electrophysiology, and β-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents

A series of novel arylpiperazines have been prepared in an attempt to incorporate both class II (β-receptor blocking) and class III antiarrhythmic properties in a single molecule. The key step in the preparation of the new compounds involves a regioselect

2-substituted-1(4)-aryl piperazines and the process for their preparation

This invention relates to novel 2-substituted-1(4)-aryl piperazines and to a process for their preparation. The compounds of this invention have been found to have cardiovascular, primarily antiarrhythmic effects and are of the following general formula I